Literature DB >> 27057049

Idiopathic Thrombocytopenic Purpura Masquerading Pediatric Systemic Lupus Erythematosus.

Mahmood Dhahir Al-Mendalawi1.   

Abstract

Entities:  

Year:  2016        PMID: 27057049      PMCID: PMC4817474          DOI: 10.4103/0019-5154.177785

Source DB:  PubMed          Journal:  Indian J Dermatol        ISSN: 0019-5154            Impact factor:   1.494


× No keyword cloud information.
Sir, I read with interest the case report by Barara and Garg on a child with systemic lupus erythematosus (SLE) who was initially presented with thrombocytopenia and diagnosed as idiopathic thrombocytopenic purpura (ITP).[1] It is worthy to mention that assessing pediatric patients, with thrombocytopenia represents a major challenge in the clinical settings as 15% of ITP patients in India, have been noticed to fulfill the diagnosis of SLE on detailed evaluation.[2] Barara and Garg stated in their study that the presence of high titer of anti-nuclear antibodies (ANA) is a sensitive marker for future development of SLE in patients with ITP.[1] They did not support that notion with references. Reviewing the literature revealed that only two studies that did not support the contribution of ANA titer to the prediction of SLE in ITP patients. The first study involved a retrospective analysis of 365 children and 108 adult patients with ITP and patients found to have positive ANA were regularly followed up for a mean of 3.6 years (range: 2.1–7 years) for the development of symptoms indicative of autoimmune disorders. The study showed that ANA positivity was often found in adult and children patients with ITP and indicated that the detection of ANA positivity was not enough to identify those patients with ITP who are at risk of developing SLE or other connective tissue diseases. Moreover, there was a statistically significant difference in terms of ANA positivity between childhood acute and chronic ITP patients. The study concluded that ANA positivity might be an indicator in terms of chronicity for childhood ITP.[3] The second study recruited 222 children with ITP who were followed for a mean of 4.2 ± 4.9 years. The study revealed that the majority of children with ITP who had a positive ANA (64%) did not develop SLE.[4] I, therefore, presume that it is essential to periodically monitor ITP patients for other clinical data of SLE rather than solely relying on ANA titer serial measurement. Apart from scrutinizing ITP patients for cutaneous lesions as recommended by Barara and Garg,[1] fever and arthralgia are additionally paramount to be regularly checked as they were proved to be the most predominant clinical characteristics in Indian SLE pediatric patients.[2]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  4 in total

1.  Case series of pediatric systemic lupus erythematosus from Kerala: comparison with other Indian series.

Authors:  Sharath Kumar; Sathyajith Nair; Lalitha Rajam
Journal:  Int J Rheum Dis       Date:  2010-10       Impact factor: 2.454

2.  Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura.

Authors:  Rawi Hazzan; Mashaand Mukamel; Joanne Yacobovich; Isaac Yaniv; Hannah Tamary
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

3.  Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura.

Authors:  Abdullah Altintas; Abdulkadir Ozel; Nilufer Okur; Nurettin Okur; Timucin Cil; Semir Pasa; Orhan Ayyildiz
Journal:  J Thromb Thrombolysis       Date:  2007-04-14       Impact factor: 2.300

4.  Idiopathic Thrombocytopenic Purpura Masquerading Paediatric SLE.

Authors:  Meenu Barara; Taru Garg
Journal:  Indian J Dermatol       Date:  2015 May-Jun       Impact factor: 1.494

  4 in total
  1 in total

1.  Analysis of clinical effects and mechanism of recombinant human interleukin-11 with glucocorticoids for treatment of idiopathic thrombocytopenic purpura.

Authors:  Xifeng Wu; Lijuan Wang; Lin Sun; Tantan Li; Xuehong Ran
Journal:  Exp Ther Med       Date:  2016-12-21       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.